JP2019536447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536447A5 JP2019536447A5 JP2019522944A JP2019522944A JP2019536447A5 JP 2019536447 A5 JP2019536447 A5 JP 2019536447A5 JP 2019522944 A JP2019522944 A JP 2019522944A JP 2019522944 A JP2019522944 A JP 2019522944A JP 2019536447 A5 JP2019536447 A5 JP 2019536447A5
- Authority
- JP
- Japan
- Prior art keywords
- population
- gene
- item
- seq
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 131
- 238000000034 method Methods 0.000 claims description 105
- 101710163270 Nuclease Proteins 0.000 claims description 60
- 108700019146 Transgenes Proteins 0.000 claims description 57
- 108091008874 T cell receptors Proteins 0.000 claims description 56
- 108091033409 CRISPR Proteins 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 43
- 239000013607 AAV vector Substances 0.000 claims description 39
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 39
- 238000010354 CRISPR gene editing Methods 0.000 claims description 35
- 101150043532 CISH gene Proteins 0.000 claims description 31
- 239000013598 vector Substances 0.000 claims description 26
- 241000702421 Dependoparvovirus Species 0.000 claims description 21
- 238000003776 cleavage reaction Methods 0.000 claims description 20
- 230000007017 scission Effects 0.000 claims description 20
- 230000005782 double-strand break Effects 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 210000004698 lymphocyte Anatomy 0.000 claims description 16
- 108091081548 Palindromic sequence Proteins 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101100385358 Alicyclobacillus acidoterrestris (strain ATCC 49025 / DSM 3922 / CIP 106132 / NCIMB 13137 / GD3B) cas12b gene Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- -1 Cpf1 Proteins 0.000 claims 1
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 claims 1
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000009613 breast lymphoma Diseases 0.000 claims 1
- 210000000234 capsid Anatomy 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 description 41
- 102000040430 polynucleotide Human genes 0.000 description 41
- 239000002157 polynucleotide Substances 0.000 description 28
- 108090000695 Cytokines Proteins 0.000 description 21
- 102000004127 Cytokines Human genes 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 230000004853 protein function Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 7
- 230000037442 genomic alteration Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022185536A JP2023010842A (ja) | 2016-10-27 | 2022-11-21 | Ｔ細胞療法のウイルス法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413814P | 2016-10-27 | 2016-10-27 | |
| US62/413,814 | 2016-10-27 | ||
| US201762452081P | 2017-01-30 | 2017-01-30 | |
| US62/452,081 | 2017-01-30 | ||
| PCT/US2017/058615 WO2018081476A2 (en) | 2016-10-27 | 2017-10-26 | Viral methods of t cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022185536A Division JP2023010842A (ja) | 2016-10-27 | 2022-11-21 | Ｔ細胞療法のウイルス法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536447A JP2019536447A (ja) | 2019-12-19 |
| JP2019536447A5 true JP2019536447A5 (enExample) | 2021-01-14 |
Family
ID=62024054
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522945A Pending JP2019531755A (ja) | 2016-10-27 | 2017-10-26 | 遺伝子改変細胞を作製するウイルス法 |
| JP2019522944A Pending JP2019536447A (ja) | 2016-10-27 | 2017-10-26 | Ｔ細胞療法のウイルス法 |
| JP2022065676A Pending JP2022087214A (ja) | 2016-10-27 | 2022-04-12 | 遺伝子改変細胞を作製するウイルス法 |
| JP2022185536A Pending JP2023010842A (ja) | 2016-10-27 | 2022-11-21 | Ｔ細胞療法のウイルス法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522945A Pending JP2019531755A (ja) | 2016-10-27 | 2017-10-26 | 遺伝子改変細胞を作製するウイルス法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065676A Pending JP2022087214A (ja) | 2016-10-27 | 2022-04-12 | 遺伝子改変細胞を作製するウイルス法 |
| JP2022185536A Pending JP2023010842A (ja) | 2016-10-27 | 2022-11-21 | Ｔ細胞療法のウイルス法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190382799A1 (enExample) |
| EP (2) | EP3532079A4 (enExample) |
| JP (4) | JP2019531755A (enExample) |
| CN (2) | CN111344396A (enExample) |
| AU (3) | AU2017347848A1 (enExample) |
| CA (2) | CA3041831A1 (enExample) |
| GB (3) | GB2607227B (enExample) |
| WO (2) | WO2018081476A2 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US20180250424A1 (en) | 2014-10-10 | 2018-09-06 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3215617B1 (en) | 2014-11-07 | 2024-05-08 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| US20180030438A1 (en) | 2015-02-23 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
| US12129471B2 (en) | 2015-02-23 | 2024-10-29 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| IL257105B (en) | 2015-07-31 | 2022-09-01 | Univ Minnesota | Modified cells and methods of therapy |
| WO2017053879A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| ES2942309T3 (es) | 2015-11-04 | 2023-05-31 | Vertex Pharma | Materiales y métodos para el tratamiento de hemoglobinopatías |
| WO2017165826A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| JP7181862B2 (ja) | 2016-10-18 | 2022-12-01 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 腫瘍浸潤リンパ球および治療の方法 |
| KR20190127655A (ko) | 2016-10-19 | 2019-11-13 | 프로디자인 소닉스, 인크. | 음향학에 의한 친화성 세포 추출 |
| GB2607227B (en) * | 2016-10-27 | 2023-05-10 | Intima Bioscience Inc | Viral methods of T cell therapy |
| CN110139675B (zh) | 2016-10-31 | 2023-09-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 用具有工程化稳定的内源性foxp3基因表达的cd4t细胞治疗自身免疫疾病的方法 |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| JP2020530307A (ja) * | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| AU2018364660B2 (en) * | 2017-11-09 | 2022-05-19 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible SH2-containing protein (CISH) gene |
| SG11202005147WA (en) | 2017-12-05 | 2020-06-29 | Vertex Pharma | Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof |
| EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
| US11713446B2 (en) * | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| EP3749767A1 (en) | 2018-02-05 | 2020-12-16 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| US11268077B2 (en) | 2018-02-05 | 2022-03-08 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| JP7558563B2 (ja) | 2018-03-15 | 2024-10-01 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
| US20210253652A1 (en) * | 2018-04-27 | 2021-08-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| WO2019210042A1 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of foxp3 in edited cd34+ cells |
| US20210130779A1 (en) | 2018-04-27 | 2021-05-06 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| AU2019262218B2 (en) * | 2018-05-03 | 2025-04-24 | Board Of Regents, The University Of Texas System | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
| WO2020018691A1 (en) * | 2018-07-18 | 2020-01-23 | The General Hospital Corporation | Modified t cells and methods of their use |
| WO2020018708A1 (en) * | 2018-07-18 | 2020-01-23 | The General Hospital Corporation | Compositions and methods for treatment of t cell malignancies |
| CN110818802B (zh) * | 2018-08-08 | 2022-02-08 | 华夏英泰（北京）生物技术有限公司 | 一种嵌合t细胞受体star及其应用 |
| US20220056479A1 (en) * | 2018-12-17 | 2022-02-24 | Cure Genetics Co., Ltd. | Method For Delivering Gene In Cells |
| WO2020163569A1 (en) * | 2019-02-08 | 2020-08-13 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Sirt2-ablated chimeric t cells |
| CN113710691B (zh) * | 2019-02-20 | 2025-03-04 | 罗格斯新泽西州立大学 | 自然杀伤和嵌合抗原受体修饰的细胞的扩增 |
| EP3931375A4 (en) * | 2019-03-01 | 2022-12-07 | Fred Hutchinson Cancer Center | Protein residue mapping using a combination of deep mutational scanning and phage display high throughput sequencing |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN113891727A (zh) * | 2019-03-27 | 2022-01-04 | 全国儿童医院研究所 | 使用cas9/rnp和aav病毒的组合来产生用于癌症免疫疗法的嵌合抗原受体（car）-原代nk细胞 |
| US20220213469A1 (en) * | 2019-04-30 | 2022-07-07 | The Broad Institute, Inc. | Methods and compositions for barcoding nucleic acid libraries and cell populations |
| CA3140393A1 (en) * | 2019-06-04 | 2020-12-10 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
| US20220275403A1 (en) * | 2019-08-19 | 2022-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods And Compositions For Enhancing AAV-Mediated Homologous Recombination Using Ribonucleotide Reductase Inhibitors |
| GB201913898D0 (en) * | 2019-09-26 | 2019-11-13 | Lightbio Ltd | Nucleic acid construct |
| JP2022552819A (ja) * | 2019-10-08 | 2022-12-20 | パクト ファーマ インコーポレイテッド | 遺伝子改変自己ｔ細胞免疫療法を使用する治療方法 |
| AU2020405203A1 (en) * | 2019-12-18 | 2022-07-14 | Editas Medicine, Inc. | Engineered cells for therapy |
| AU2021227663A1 (en) * | 2020-02-28 | 2022-09-22 | Genentech, Inc. | Efficient genome editing in primary myeloid cells |
| CN111420025B (zh) * | 2020-04-28 | 2021-06-11 | 中国药科大学 | 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用 |
| KR20230017786A (ko) | 2020-04-28 | 2023-02-06 | 라이엘 이뮤노파마, 인크. | 세포 배양 방법 |
| IL298510A (en) | 2020-06-12 | 2023-01-01 | Nkarta Inc | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| WO2022118310A1 (en) * | 2020-12-01 | 2022-06-09 | Lepton Pharmaceuticals Ltd. | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
| US20230407337A1 (en) * | 2020-12-08 | 2023-12-21 | The Regents if the University of California | Crispr ribonucleoprotein complex genome editing of human innate immune cells |
| CN113046357B (zh) * | 2021-01-25 | 2023-05-16 | 柳州市柳铁中心医院 | 一种乐伐替尼耐药基因dusp9、其筛选方法及应用 |
| CN112941105A (zh) * | 2021-02-08 | 2021-06-11 | 江西农业大学 | 一种m6A“阅读器”YTHDF2基因改造方法及其应用 |
| CN114058619B (zh) * | 2021-11-19 | 2023-11-14 | 中国农业科学院兰州兽医研究所 | Riplet敲除细胞系的构建及作为小核糖核酸病毒科病毒疫苗生产细胞系的应用 |
| CN114621929B (zh) * | 2021-12-21 | 2023-05-30 | 河南省肿瘤医院 | 一种抗肿瘤树突状细胞及其制备方法、表达载体及应用 |
| US20250197826A1 (en) * | 2022-03-16 | 2025-06-19 | Regents Of The University Of Minnesota | Genetically engineered t cell for cell therapy |
| CN119923264A (zh) * | 2022-09-27 | 2025-05-02 | 基因泰克公司 | 抑制基因毒性应激以改善t细胞工程化 |
| EP4661970A1 (en) * | 2023-02-07 | 2025-12-17 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Therapeutic base editing |
| WO2024220789A1 (en) * | 2023-04-21 | 2024-10-24 | Regents Of The University Of Minnesota | Cell lines and methods for producing recombinant adeno-associated virus |
| WO2025179160A1 (en) * | 2024-02-21 | 2025-08-28 | Research Institute At Nationwide Children's Hospital | Methods of increasing nk cell efficacy through inhibition of v-domain ig suppressor of t cell activation (vista) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012078540A1 (en) * | 2010-12-08 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1 |
| EP3763810A3 (en) * | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US9937207B2 (en) * | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| AU2014262469B2 (en) * | 2013-05-10 | 2019-11-14 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| CN105378067A (zh) * | 2013-05-13 | 2016-03-02 | 塞勒克提斯公司 | 工程化用于免疫治疗的高活性t细胞的方法 |
| WO2015057980A1 (en) * | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| KR102827558B1 (ko) * | 2014-04-18 | 2025-07-11 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분 |
| CN107206024B (zh) * | 2014-10-31 | 2021-12-03 | 宾夕法尼亚大学董事会 | 改变cart细胞中的基因表达及其用途 |
| CA2985650A1 (en) * | 2015-05-13 | 2016-11-17 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Enhancing endonuclease based gene editing in primary cells |
| IL257105B (en) * | 2015-07-31 | 2022-09-01 | Univ Minnesota | Modified cells and methods of therapy |
| US20190241910A1 (en) * | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| PT4180519T (pt) * | 2016-04-15 | 2025-09-04 | Memorial Sloan Kettering Cancer Center | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
| WO2018073391A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| GB2607227B (en) * | 2016-10-27 | 2023-05-10 | Intima Bioscience Inc | Viral methods of T cell therapy |
| JP2020530307A (ja) * | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| AU2018364660B2 (en) * | 2017-11-09 | 2022-05-19 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible SH2-containing protein (CISH) gene |
-
2017
- 2017-10-26 GB GB2210377.4A patent/GB2607227B/en active Active
- 2017-10-26 CA CA3041831A patent/CA3041831A1/en active Pending
- 2017-10-26 GB GB1906849.3A patent/GB2573663B/en active Active
- 2017-10-26 JP JP2019522945A patent/JP2019531755A/ja active Pending
- 2017-10-26 EP EP17865054.5A patent/EP3532079A4/en not_active Withdrawn
- 2017-10-26 WO PCT/US2017/058615 patent/WO2018081476A2/en not_active Ceased
- 2017-10-26 EP EP17865925.6A patent/EP3532075A4/en not_active Withdrawn
- 2017-10-26 GB GB1906850.1A patent/GB2573664B/en active Active
- 2017-10-26 AU AU2017347848A patent/AU2017347848A1/en not_active Abandoned
- 2017-10-26 JP JP2019522944A patent/JP2019536447A/ja active Pending
- 2017-10-26 CN CN201780082010.6A patent/CN111344396A/zh active Pending
- 2017-10-26 CA CA3041835A patent/CA3041835A1/en active Pending
- 2017-10-26 AU AU2017347854A patent/AU2017347854B2/en active Active
- 2017-10-26 CN CN201780082012.5A patent/CN110545827A/zh active Pending
- 2017-10-26 WO PCT/US2017/058605 patent/WO2018081470A1/en not_active Ceased
-
2019
- 2019-04-19 US US16/389,612 patent/US20190382799A1/en not_active Abandoned
- 2019-04-19 US US16/389,586 patent/US20190374576A1/en not_active Abandoned
-
2022
- 2022-04-12 JP JP2022065676A patent/JP2022087214A/ja active Pending
- 2022-11-21 JP JP2022185536A patent/JP2023010842A/ja active Pending
-
2023
- 2023-02-28 AU AU2023201224A patent/AU2023201224A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536447A5 (enExample) | ||
| JP2023010842A (ja) | Ｔ細胞療法のウイルス法 | |
| JP2023055884A5 (enExample) | ||
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| US11186825B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 | |
| Malouli et al. | Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy | |
| US11180730B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 | |
| JP2019531755A5 (enExample) | ||
| JP2018522072A5 (enExample) | ||
| JPWO2019178422A5 (enExample) | ||
| AU2021411521A9 (en) | Engineered t cells | |
| JPWO2020163365A5 (enExample) | ||
| WO2022012531A1 (zh) | 一种经修饰的免疫细胞的制备方法 | |
| Pierce et al. | Adenovirus early region 3 antiapoptotic 10.4 K, 14.5 K, and 14.7 K genes decrease the incidence of autoimmune diabetes in NOD mice | |
| US20090060889A1 (en) | Ii-RNAi involved Ii suppression in cancer immunotherapy | |
| US20240366668A1 (en) | Nkg2d car cells expressing il-18 for adoptive cell therapy | |
| WO2020164167A1 (zh) | 一种用于通用型car-t制备的重组腺相关病毒载体及其构建方法和应用 | |
| Wang et al. | Rational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators | |
| CN1807647A (zh) | rep基因表达质粒，RBE顺式元件定点整合体系及其制备方法和应用 | |
| HK40032623A (en) | Viral methods of making genetically modified cells | |
| HK40018037A (en) | Viral methods of t cell therapy | |
| NZ547388A (en) | Use of interfering RNA in the production of transgenic animals |